Atlas Trials

Ruxolitinib as First Line Treatment in Primary Haemophagocytic Lymphohistiocytosis (R-HLH)

Clinical trial NCT05762640 · RECRUITING

Trial details

NCT number
NCT05762640
Sponsor
Assistance Publique - Hôpitaux de Paris
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Haemophagocytic Lymphohistiocytosis
Start date
2024-11-10
Primary completion
2027-05-01
Enrollment
20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.